Eight months after the introduction of Note 97 for the prescription of oral anticoagulant therapy in patients with non-valvular atrial fibrillation (NVAF), the Agency’s monitoring shows that there have been no major increases in the number of prescriptions for subjects benefiting from new oral anticoagulants (NOAs), up by 6.1% in the comparison between the period before and after the application of the Note. The impact of Note 97 can therefore be considered sustainable (including in economic terms).